智通财经APP获悉，翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。
消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐® (甲磺酸阿美替尼片)获中国国家药品监督管理局(“NMPA”)签发的药品注册证书，批准增加“阿美乐®联合培美曲塞和铂类化疗药物适用于具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子 21(L858R)置换突变的局部晚期或转移性非小细胞肺癌(“NSCLC”)成人患者的一线治疗”适应症。此为阿美乐®获批的第五项适应症。
值得一提的是，据翰森制药官微消息，近日，国际顶级肿瘤学期刊《Lancet Oncology》(中文译名：《柳叶刀·肿瘤学》，影响因子：35.9)在线重磅发布了翰森制药创新药阿美乐®(甲磺酸阿美替尼片，110mg)用于EGFR突变非小细胞肺癌辅助治疗的最新研究结果。数据显示，阿美乐®能够显著改善完全切除的Ⅱ-ⅢB期EGFR突变NSCLC患者的无病生存期(DFS)，且安全性良好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.